These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 9789288)

  • 41. Prevention of multiple organ dysfunction syndrome in patients with extensive deep burns.
    Sheng Z
    Chin J Traumatol; 2002 Aug; 5(4):195-9. PubMed ID: 12162895
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pathophysiology of septic shock and multiple organ dysfunction syndrome and various therapeutic approaches with special emphasis on immunoglobulins.
    Werdan K
    Ther Apher; 2001 Apr; 5(2):115-22. PubMed ID: 11354295
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of the tissue factor pathway in the pathogenesis and management of multiple organ failure.
    Smithies MN; Weaver CB
    Blood Coagul Fibrinolysis; 2004 May; 15 Suppl 1():S11-20. PubMed ID: 15166928
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Endotoxin removal therapy with Polymyxin B immobilized fiber column as a COVID-19-bedside strategy protocol for endotoxic shock.
    De Rosa S; Zanella M; Samoni S; Ronco C
    Front Nephrol; 2022; 2():847305. PubMed ID: 37675016
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pathogenesis of multiple organ dysfunction syndrome--endotoxin, inflammatory cells, and their mediators: cytokines and reactive oxygen species.
    Maier RV
    Surg Infect (Larchmt); 2000; 1(3):197-204; discussion 204-5. PubMed ID: 12594890
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antithrombotic Agents in the Management of Sepsis.
    Iqbal O; Tobu M; Hoppenstead D; Aziz S; Messmore H; Fareed J
    Turk J Haematol; 2002 Sep; 19(3):349-89. PubMed ID: 27264974
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Acute pancreatitis as a model of sepsis.
    Wilson PG; Manji M; Neoptolemos JP
    J Antimicrob Chemother; 1998 Jan; 41 Suppl A():51-63. PubMed ID: 9511087
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Endotoxin, sepsis, and the primrose path.
    O'Reilly M; Newcomb DE; Remick D
    Shock; 1999 Dec; 12(6):411-20. PubMed ID: 10588508
    [No Abstract]   [Full Text] [Related]  

  • 49. Pathogenesis of Multiple Organ Failure in Sepsis.
    Rossaint J; Zarbock A
    Crit Rev Immunol; 2015; 35(4):277-91. PubMed ID: 26757392
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A systematic review of experimental treatments for mitochondrial dysfunction in sepsis and multiple organ dysfunction syndrome.
    Dare AJ; Phillips AR; Hickey AJ; Mittal A; Loveday B; Thompson N; Windsor JA
    Free Radic Biol Med; 2009 Dec; 47(11):1517-25. PubMed ID: 19715753
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sequential Extracorporeal Therapy in Sepsis.
    De Rosa S; Cutuli SL; Lorenzin A; Zanella M
    Contrib Nephrol; 2023; 200():149-159. PubMed ID: 37290408
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Extracorporeal blood purification therapy for sepsis and systemic inflammation: its biological rationale.
    Bellomo R; Baldwin I; Ronco C
    Contrib Nephrol; 2001; (132):367-74. PubMed ID: 11395904
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pathogenesis and treatment of multiorgan failure dysfunction syndrome in shock.
    Ciesielski L; Modzelewski B
    Rocz Akad Med Bialymst; 1995; 40(1):13-24. PubMed ID: 8528983
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The failure of biologics in sepsis: where do we stand?
    Giamarellos-Bourboulis EJ
    Int J Antimicrob Agents; 2013 Jun; 42 Suppl():S45-7. PubMed ID: 23664229
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gut Microbiota and Multiple Organ Dysfunction Syndrome (MODS).
    Chen P; Billiar T
    Adv Exp Med Biol; 2020; 1238():195-202. PubMed ID: 32323186
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Multiple Organ Dysfunction: The Defining Syndrome of Sepsis.
    Ziesmann MT; Marshall JC
    Surg Infect (Larchmt); 2018; 19(2):184-190. PubMed ID: 29360419
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Usefulness of haemoperfusion in the treatment of the severe septic patient: an update].
    Pestaña D; Ojeda N; Padrón OM; Higuera E; Rey T; Aldecoa C;
    Rev Esp Anestesiol Reanim; 2013; 60(6):336-43. PubMed ID: 23044210
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bench-to-bedside review: sepsis - from the redox point of view.
    Andrades MÉ; Morina A; Spasić S; Spasojević I
    Crit Care; 2011; 15(5):230. PubMed ID: 21996422
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of enhanced adsorption haemofiltration versus haemoadsorption in severe, refractory septic shock with high levels of endotoxemia: the ENDoX bicentric, randomized, controlled trial.
    Wendel-Garcia PD; Eberle B; Kleinert EM; Hilty MP; Blumenthal S; Spanaus K; Fodor P; Maggiorini M
    Ann Intensive Care; 2023 Dec; 13(1):127. PubMed ID: 38095800
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro comparison of the adsorption of inflammatory mediators by blood purification devices.
    Malard B; Lambert C; Kellum JA
    Intensive Care Med Exp; 2018 May; 6(1):12. PubMed ID: 29728790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.